SP2-1 The impact of COVID-19 on cancer treatment in Japan; actual condition, countermeasure, and task

por Sunakawa, Yu
Publicado 2021

Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives

por Takeda, Hiroyuki, Sunakawa, Yu
Publicado 2021

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors

por Sunakawa, Yu, Satake, Hironaga, Ichikawa, Wataru
Publicado 2018

Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies

por Sunakawa, Yu, Takahashi, Keishiro, Kawaguchi, Osamu, Yamamoto, Nobuyuki
Publicado 2022

“Phantom akathisia” in an amputated leg of a sarcoma patient: a case report

por Ishida, Mayumi, Imanishi, Jungo, Yazawa, Yasuo, Sunakawa, Yu, Torigoe, Tomoaki, Onishi, Hideki
Publicado 2020

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors

por García-Foncillas, Jesús, Sunakawa, Yu, Aderka, Dan, Wainberg, Zev, Ronga, Philippe, Witzler, Pauline, Stintzing, Sebastian
Publicado 2019

Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer

por Doi, Ayako, Mizukami, Takuro, Takeda, Hiroyuki, Umemoto, Kumiko, Arai, Hiroyuki, Horie, Yoshiki, Izawa, Naoki, Ogura, Takashi, Sunakawa, Yu
Publicado 2023

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study

por Kodera, Yasuhiro, Yoshida, Kazuhiro, Kochi, Mitsugu, Sano, Takeshi, Ichikawa, Wataru, Kakeji, Yoshihiro, Sunakawa, Yu, Takeuchi, Masahiro, Fujii, Masashi
Publicado 2023

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy

por Sunakawa, Yu, Izawa, Naoki, Mizukami, Takuro, Horie, Yoshiki, Hirakawa, Mami, Arai, Hiroyuki, Ogura, Takashi, Tsuda, Takashi, Nakajima, Takako Eguchi
Publicado 2017

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

por Sunakawa, Yu, Furuse, Junji, Okusaka, Takuji, Ikeda, Masafumi, Nagashima, Fumio, Ueno, Hideki, Mitsunaga, Shuichi, Hashizume, Kensei, Ito, Yuichiro, Sasaki, Yasutsuna
Publicado 2013

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

por Sunakawa, Yu, Furuse, Junji, Okusaka, Takuji, Ikeda, Masafumi, Nagashima, Fumio, Ueno, Hideki, Mitsunaga, Shuichi, Hashizume, Kensei, Ito, Yuichiro, Sasaki, Yasutsuna
Publicado 2013

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition

por Ebi, Hiromichi, Bando, Hideaki, Taniguchi, Hiroya, Sunakawa, Yu, Okugawa, Yoshinaga, Hatanaka, Yutaka, Hosoda, Waki, Kumamoto, Kensuke, Nakatani, Kaname, Yamazaki, Kentaro
Publicado 2020

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib

por Arai, Hiroyuki, Miyakawa, Kunihisa, Denda, Tadamichi, Mizukami, Takuro, Horie, Yoshiki, Izawa, Naoki, Hirakawa, Mami, Ogura, Takashi, Tsuda, Takashi, Sunakawa, Yu, Nakajima, Takako Eguchi
Publicado 2017

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer

por Sebio, Ana, Matsusaka, Satoshi, Zhang, Wu, Yang, Dongyun, Ning, Yan, Stremitzer, Stefan, Stintzing, Sebastian, Sunakawa, Yu, Yamauchi, Shinichi, Fujimoto, Yoshiya, Ueno, Masashi, Lenz, Heinz-Josef
Publicado 2015

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

por Sasaki, Yasutsuna, Miwa, Keisuke, Yamashita, Keishi, Sunakawa, Yu, Shimada, Ken, Ishida, Hiroo, Hasegawa, Kosei, Fujiwara, Keiichi, Kodaira, Makoto, Fujiwara, Yasuhiro, Namiki, Masayuki, Matsuda, Minami, Takeuchi, Yutaka, Katsumata, Noriyuki
Publicado 2014

Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report

por Doi, Ayako, Takeda, Hiroyuki, Umemoto, Kumiko, Oumi, Ryosuke, Wada, Shinji, Hamaguchi, Shingo, Mimura, Hidefumi, Arai, Hiroyuki, Horie, Yoshiki, Mizukami, Takuro, Izawa, Naoki, Ogura, Takashi, Nakajima, Takako Eguchi, Sunakawa, Yu
Publicado 2020

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX

por Kaga, Yasuhiro, Sunakawa, Yu, Kubota, Yutaro, Tagawa, Teppei, Yamamoto, Taikan, Ikusue, Toshikazu, Uto, Yu, Miyashita, Kouichirou, Toshima, Hirokazu, Kobayashi, Kouji, Hisamatsu, Atsushi, Ichikawa, Wataru, Sekikawa, Takashi, Shimada, Ken, Sasaki, Yasutsuna
Publicado 2016

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS...

por Nakajima, Hiromichi, Kotani, Daisuke, Bando, Hideaki, Kato, Takeshi, Oki, Eiji, Shinozaki, Eiji, Sunakawa, Yu, Yamazaki, Kentaro, Yuki, Satoshi, Nakamura, Yoshiaki, Yamanaka, Takeharu, Yoshino, Takayuki, Ohta, Takashi, Taniguchi, Hiroya, Kagawa, Yoshinori
Publicado 2021

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients

por Volz, Nico B., Hanna, Diana L., Stintzing, Sebastian, Zhang, Wu, Yang, Dongyun, Cao, Shu, Ning, Yan, Matsusaka, Satoshi, Sunakawa, Yu, Berger, Martin D., Cremolini, Chiara, Loupakis, Fotios, Falcone, Alfredo, Lenz, Heinz-Josef
Publicado 2020

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

por Satake, Hironaga, Sunakawa, Yu, Miyamoto, Yuji, Nakamura, Masato, Nakayama, Hiroshi, Shiozawa, Manabu, Makiyama, Akitaka, Kobayashi, Kazuma, Kubota, Yutaro, Mori, Misuzu, Kotaka, Masahito, Takagane, Akinori, Gotoh, Masahiro, Takeuchi, Masahiro, Fujii, Masashi, Ichikawa, Wararu, Sekikawa, Takashi
Publicado 2018